Legis Daily

Infectious Disease Therapies Research and Innovation Act of 2022

USA117th CongressHR-7515| House 
| Updated: 4/14/2022
Mike Kelly

Mike Kelly

Republican Representative

Pennsylvania

Cosponsors (2)
Brad R. Wenstrup (Republican)Vern Buchanan (Republican)

Ways and Means Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Infectious Disease Therapies Research and Innovation Act of 2022 This bill exempts from the definition of passive activity , for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity. The bill defines specified medical research small business pass-thru entity as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than $1 million.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-7537
Infectious Disease Therapies Research and Innovation Act of 2020
Apr 14, 2022
Introduced in House
Apr 14, 2022
Referred to the House Committee on Ways and Means.
  • Bill from Previous Congress

    HR 116-7537
    Infectious Disease Therapies Research and Innovation Act of 2020


  • April 14, 2022
    Introduced in House


  • April 14, 2022
    Referred to the House Committee on Ways and Means.

Taxation

Infectious Disease Therapies Research and Innovation Act of 2022

USA117th CongressHR-7515| House 
| Updated: 4/14/2022
Infectious Disease Therapies Research and Innovation Act of 2022 This bill exempts from the definition of passive activity , for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity. The bill defines specified medical research small business pass-thru entity as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than $1 million.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-7537
Infectious Disease Therapies Research and Innovation Act of 2020
Apr 14, 2022
Introduced in House
Apr 14, 2022
Referred to the House Committee on Ways and Means.
  • Bill from Previous Congress

    HR 116-7537
    Infectious Disease Therapies Research and Innovation Act of 2020


  • April 14, 2022
    Introduced in House


  • April 14, 2022
    Referred to the House Committee on Ways and Means.
Mike Kelly

Mike Kelly

Republican Representative

Pennsylvania

Cosponsors (2)
Brad R. Wenstrup (Republican)Vern Buchanan (Republican)

Ways and Means Committee

Taxation

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted